1-20 of 27
Maxwell Sehested
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 832: Suicide gene therapy is effective for treating chemo-resistant small cell lung cancer cells

Signe R. Michaelsen, Camilla L. Christensen, Maxwell Sehested, Frederik Cramer, Thomas T. Poulsen, Hans S. Poulsen
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 832.
https://doi.org/10.1158/1538-7445.AM2012-832
Published: 15 April 2012
View article titled, Abstract 832: Suicide gene therapy is effective for treating chemo-resistant small cell lung cancer cells
Journal Articles

Abstract 5320: Changes in [18]F-FLT and [18]F-FDG positron emission tomography following treatment with belinostat alone and in combination with paclitaxel/carboplatin in human ovary cancer xenografts in mice

Mette Munk Jensen, Kamille Dumong Erichsen, Camilla Bardram Johnbeck, Fredrik Björkling, Jacob Madsen, Peter Buhl Jensen, Maxwell Sehested, Liselotte Højgaard, Andreas Kjær
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 5320.
https://doi.org/10.1158/1538-7445.AM2011-5320
Published: 15 April 2011
View article titled, Abstract 5320: Changes in [18]F-FLT and [18]F-FDG positron emission tomography following treatment with belinostat alone and in combination with paclitaxel/carboplatin in human ovary cancer xenografts in mice
Journal Articles

Abstract 5220: Early prediction of tumor response to APO866 treatment with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography in human ovary cancer xenografts in mice

Mette Munk Jensen, Kamille Dumong Erichsen, Fredrik Björkling, Jacob Madsen, Liselotte Højgaard, Maxwell Sehested, Andreas Kjær
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 5220.
https://doi.org/10.1158/1538-7445.AM10-5220
Published: 15 April 2010
View article titled, Abstract 5220: Early prediction of tumor response to APO866 treatment with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography in human ovary cancer xenografts in mice
Journal Articles

Abstract #5519: Characterization of novel nicotinamide dinucleotide synthesis inhibitor TP201565 and cellular resistance mechanisms

Uffe Olesen, Annemette Thougaard, Mette Christensen, Fredrik Björkling, Jette Tjørnelund, Morten Persson, Kamille Petersen, Søren Nielsen, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 5519.
Published: 01 May 2009
View article titled, Abstract #5519: Characterization of novel nicotinamide dinucleotide synthesis inhibitor TP201565 and cellular resistance mechanisms
Journal Articles

Dexrazoxane protects against daunorubicin induced hematotoxicity in male beagle dogs

Kenneth Hofland, Ib Christensen, Annemette Thougaard, Kamille Petersen, Morten Grauslund, Lars Jensen, Maxwell Sehested, Peter Jensen
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 1567.
Published: 01 May 2007
View article titled, Dexrazoxane protects against daunorubicin induced hematotoxicity in male beagle dogs
Journal Articles

Gene expression screen in cell panel selected for varying sensitivity towards the Histone DeACetylase inhibitor (HDACi) PXD101 reveals potential predictors of HDACi sensitivity

Marielle Dejligbjerg, Ib Christensen, Morten Grauslund, Peter Jensen, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 687.
Published: 01 May 2007
View article titled, Gene expression screen in cell panel selected for varying sensitivity towards the Histone DeACetylase inhibitor (HDACi) PXD101 reveals potential predictors of HDACi sensitivity
Journal Articles

Expression of histone deacetylases 1 and 2 and histone 4 acetylation in T- and B-cell lymphomas

Lena Ipsen, Lise Mette Gjerdrum, Christian Poulsen, Peter Jensen, Maxwell Sehested, Elisabeth Ralfki?r
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 174.
Published: 01 May 2007
View article titled, Expression of histone deacetylases 1 and 2 and histone 4 acetylation in T- and B-cell lymphomas
Journal Articles

Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis

Frederic Tort, Jirina Bartkova, Maxwell Sehested, Torben Ørntoft, Jiri Lukas, Jiri Bartek
Journal: Cancer Research
Cancer Res (2006) 66 (21): 10258–10263.
https://doi.org/10.1158/0008-5472.CAN-06-2178
Published: 01 November 2006
View article titled, Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis
Open the PDF for Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis in another window
Includes: Supplementary data
Journal Articles

A transgenic mouse model for analyzing the role of topoisomerase II in mediating the pharmacological effects of dexrazoxane.

Morten Grauslund, Annemette V. Thougaard, Annette Füchtbauer, Kenneth F. Hofland, Peter Hjorth, Seppo Langer, Peter B. Jensen, Lars H. Jensen, Ernst-Martin Füchtbauer, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1298.
Published: 15 April 2006
View article titled, A transgenic mouse model for analyzing the role of topoisomerase II in mediating the pharmacological effects of dexrazoxane.
Journal Articles

SAR analysis of substituted purines as topoisomerase II inhibitors identifies ATPase inhibitors with nanomolar activity.

Lars H. Jensen, Peter B. Jensen, Robert H. Shoemaker, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1301.
Published: 15 April 2006
View article titled, SAR analysis of substituted purines as topoisomerase II inhibitors identifies ATPase inhibitors with nanomolar activity.
Journal Articles

Activity of the HDAC inhibitor, PXD101, used as monotherapy and combination therapy in preclinical NSCLC studies

Xiaozhong Qian, William J. Larochelle, Gulshan Ara, Maxwell Sehested, Henri S. Lichestein, Michael Jeffers
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1114.
Published: 15 April 2006
View article titled, Activity of the HDAC inhibitor, PXD101, used as monotherapy and combination therapy in preclinical NSCLC studies
Journal Articles

Plasma and cerobrospinal fluid (CSF) pharmacokinetics of the histone deacetylase (HDAC) inhibitor, PXD101, in non-human primates

Katherine E. Warren, Cindy M. McCully, Henrik Dvinge, Maxwell Sehested, Jette Tjørnelund, Henri S. Lichenstein, Frank M. Balis
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 727–728.
Published: 15 April 2006
View article titled, Plasma and cerobrospinal fluid (CSF) pharmacokinetics of the histone deacetylase (HDAC) inhibitor, PXD101, in non-human primates
Journal Articles

Substituted Purine Analogues Define a Novel Structural Class of Catalytic Topoisomerase II Inhibitors

Lars H. Jensen, Annemette V. Thougaard, Morten Grauslund, Birgitte Søkilde, Elisabeth V. Carstensen, Henrik K. Dvinge, Dominic A. Scudiero, Peter B. Jensen, Robert H. Shoemaker, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2005) 65 (16): 7470–7477.
https://doi.org/10.1158/0008-5472.CAN-05-0707
Published: 15 August 2005
View article titled, Substituted Purine Analogues Define a Novel Structural Class of Catalytic Topoisomerase II Inhibitors
Open the PDF for Substituted Purine Analogues Define a Novel Structural Class of Catalytic Topoisomerase II Inhibitors in another window
Journal Articles

A C6-substituted guanine analog defines a novel class of ATP catalytic topoisomerase II inhibitors

Lars H. Jensen, Annemette Tuogaard, Birgitte Sokilde, Henrik K. Dvinge, Morten Grauslund, Elisabeth V. Carstensen, Eric Santoni-Rugiu, Dominic A. Scudiero, Robert H. Shoemaker, Peter B. Jensen, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 933–934.
Published: 01 May 2005
View article titled, A C6-substituted guanine analog defines a novel class of ATP catalytic topoisomerase II inhibitors
Journal Articles

Development of resistance in the murine leukemia cell-line P388 towards the hydroxamate histone deacetylase inhibitor PXD101

Torsten H. Nielsen, Nick Edwards, Marielle Dejligbjerg, Mike Jeffers, Peter B. Jensen, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 423–424.
Published: 01 May 2005
View article titled, Development of resistance in the murine leukemia cell-line P388 towards the hydroxamate histone deacetylase inhibitor PXD101
Journal Articles

Dexrazoxane does not affect pharmacokinetics of high-dose etoposide in patients with brain metastases

Kenneth F. Hofland, Henrik Dvinge, Jette Tjørnelund, Birgitte Søkilde, Maxwell Sehested, Peter B. Jensen
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 941–942.
Published: 01 May 2005
View article titled, Dexrazoxane does not affect pharmacokinetics of high-dose etoposide in patients with brain metastases
Journal Articles

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit tumour cell growth in vitro and in vivo

Tony Tumber, Laura Collins, Kamille Petersen, Annemette Thougaard, Marielle Dejligbjerg, Sanne Christiansen, Peter Buhl-Jensen, Paul Finn, Maxwell Sehested, James Ritchie
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1202–1203.
Published: 01 May 2005
View article titled, The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit tumour cell growth <em>in vitro</em> and <em>in vivo</em>
Journal Articles

Cerebral chemo-radiotherapy with etoposide and dexrazoxane increase survival in mice with brain-tumour

Kenneth F. Hofland, Maxwell Sehested, Paul E. G. Kristjansen, Annemette V. Thougaard, Pia Rengtved, Peter B. Jensen
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 313.
Published: 01 April 2004
View article titled, Cerebral chemo-radiotherapy with etoposide and dexrazoxane increase survival in mice with brain-tumour
Journal Articles

DNA Damage-activated Kinase Chk2 Is Independent of Proliferation or Differentiation Yet Correlates with Tissue Biology

Claudia Lukas, Jirina Bartkova, Lucia Latella, Jacob Falck, Niels Mailand, Tine Schroeder, Maxwell Sehested, Jiri Lukas, Jiri Bartek
Journal: Cancer Research
Cancer Res (2001) 61 (13): 4990–4993.
Published: 01 July 2001
View article titled, DNA Damage-activated Kinase Chk2 Is Independent of Proliferation or Differentiation Yet Correlates with Tissue Biology
Open the PDF for DNA Damage-activated Kinase Chk2 Is Independent of Proliferation or Differentiation Yet Correlates with Tissue Biology in another window
Journal Articles

Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the α Isoform

Irene Wessel, Lars H. Jensen, Peter B. Jensen, Jacob Falck, Angela Rose, Mikael Roerth, John L. Nitiss, Maxwell Sehested
Journal: Cancer Research
Cancer Res (1999) 59 (14): 3442–3450.
Published: 15 July 1999
View article titled, Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the α Isoform
Open the PDF for Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the α Isoform in another window